Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
CGM Simplicity Can Be Complex Information for Beginners
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Lisa Latts on Watson AI and Diabetes Care
Your Votes Needed!
HOMERUN SLIDES — Great Clinical Presentation Highlights
Diabetes Apps Presentation Part 2
CLINICAL GEMS — The Best from Diabetes Texts
A COLLABORATIVE APPROACH TO DIABETES CARE V APRIL 4-5, 2019 CHARLESTON, SC
A cross continuum of inpatient diabetes care. Hospitals are being incentivized for achieving diabetes care metrics in the patient population in their catchment area which has required them to develop effective healthcare delivery models that impact not only just individual patients but also the patient population as a whole. Hear case studies from Mayo Clinic, MD Anderson, UPMC, Allina Healthcare, Essentia Health and more. Learn about transitioning of care, building and maintaining Inpatient Diabetes Programs and Management, incorporating Triple Aim, diabetes prevention programs, ROI for Tele Diabetes, collaborative diabetes depression models, incorporating SOCIAL DETERMINANTS OF HEALTH measures, financial impact of low literacy on a healthcare system, Cardiovascular risk associated with diabetes and inpatient care, cancer risk associated with diabetes and the inpatient care, managing diabetes in hospitalized patients with chronic Kidney Disease and more. For complete conference details including discounts available for Diabetes In Control Members, click here.
MOST POPULAR ARTICLES OF THE MONTH
#1 Warn, Teach, and Revisit Metformin
#2 Confusing Insulins Still A Common Mistake
#3 What Can Happen When Patients Take Diabetes Holidays
Editor's Note
Our good friend at Diabetes Investor, David Kliff, has made a point of focusing on the difficulty of a patient’s success just because we have “whizbang” apps and devices to make glucose control almost automatic.
The data shows he is probably right, as keeping patients on medications and causing them to want to improve has a much bigger effect than having an app.
This week, Steve interviews Dr. Lisa Latts, a practicing physician and Deputy Chief Health Officer at Watson Health IBM. Dr. Latts presents a different picture of the use of apps and AI for successfully managing diabetes and her insight might just surprise you.
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
Woman, 55 years of age visited with me 3 weeks ago. Her glucose levels were in the 200-250 mg/dL range. She was actually a new patient of ours; her A1C was 9.2%. We recommended a CGM. She purchased one and brought it to the office for me to teach her how to use it. I did so. This patient is well-educated and seemed tech-savvy. When she left the visit, she “seemed” to understand CGM, what it is, what to do, and how to insert the sensor, get readings, interpret readings, etc.
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Lisa M. Latts MD, MSPH, MBA, FACP is Deputy Chief Health Officer for IBM Watson Health. She is a national leader in health care quality and has nearly 20 years’ experience in health care delivery working to improve lives for patients. She has worked as a health insurance executive, a consultant and for one of the nation’s leading academic medical centers helping to deliver high quality care to its faculty and employees. She is currently helping IBM Watson Health bring cognitive computing and machine learning to advance the idea of Value-Based Care and help solve the pressing problems that physicians, employers and payers are facing.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, we determine what makes a diabetes app useful.
CLINICAL GEMS — The Best from Diabetes Texts
The relationship between pathogenic factors and beta-cell destruction remains poorly understood. Longitudinal studies of newborns and children at genetic risk and follow-up of at-risk first-degree relatives in natural history studies link the triggering of autoimmunity with the appearance of autoantibodies to one or more islet autoantigens; individuals with multiple autoantibodies have higher risk of diabetes progression.
Your Votes Needed!
Which of the following items would you be interested in seeing added to DIC?
MOST POPULAR ARTICLES OF THE MONTH
If this happens in my practice, I’m sure it likely happens with your patients too.
So many of our patients take metformin. They may be new to using metformin or have been taking it for many years. Either way it’s not unusual to have untoward GI side effects from taking it. They may have done fine taking it for years, so they don’t even think about it being their metformin.
I have a patient who has type 2 diabetes. He was started on long-acting insulin 8 months ago. Before adding the insulin, he was taking a daily GLP-1. He had experienced diabetic ketoacidosis (DKA) while on a SGLT-2, and did not tolerate metformin due to GI side effects. Therefore, these two were no longer options. …
Man, 36 years of age, type 2 diabetes, obesity class II, fatty liver, was taking metformin 1,000mg twice daily, and lower dose of SGLT-2. A1C was elevated 9% due to steroids; had been in the 6-7% range. Came in for 3-month follow up — A1C 9.9%, glucose 359, urine positive for glucose and for ketones, gained 19 pounds since last office visit, B/P 126/78-HR 78 and regular.
The patient reports he took a “holiday” from everything during the holidays. He ate and drank anything and everything he wanted, including alcohol, and stopped his medications. He complained of increased hunger and thirst. Very thirsty.